The next generation of FSP will be defined by results, not headcount

When introduced, Functional Service Provider (FSP) outsourcing was used primarily for staff augmentation — a solution for a single challenge. But the clinical development environment for which this model was created has changed significantly. While biotech and biopharma organizations still need ways to access additional talent, many of the leaders I speak with today are facing broader challenges and opportunities. 

The legacy approach to FSP doesn’t meet enough of their needs. As our customers face growing pre- and post-approval pressures, they need outsourcing options that will evolve alongside their businesses to provide expertise, innovation and scale. 

Those conversations are a big part of why I see such opportunity in Parexel FSP Integrated Solutions. By combining world-class talent, integrated expertise, AI-enabled capabilities and rigorous process governance, we help sponsors extend both capacity and capability while delivering the outcomes that matter most. 

The outsourcing evolution

As drug development programs and post-approval commitments become increasingly complex, organizations are rethinking and refining their operating models to identify opportunities for increased productivity. Consequently, they’re rethinking outsourcing options as well.

It’s time to move away from transactional, headcount-based approaches. Sponsors need a better path forward: Enterprise Capability Partners that take accountability for outcomes, provide access to specialized expertise, and help them build operating models that can adapt as their business evolves.

This requires a different kind of partnership. The CRO's role expands beyond providing resources to enabling sponsors to improve productivity, access specialized expertise, support their innovation roadmap development, and evolve their operating models. Value comes from: 

• Specialized expertise and strategic insight, spanning clinical development, biometrics, data management, regulatory, safety, medical writing and post-approval lifecycle activities
• Technology-enabled execution that improves productivity, quality and operational performance
• Access to innovation through Parexel's ongoing investments in technology, AI-enabled capabilities and strategic partnerships
• Adaptable operating models that evolve alongside changing portfolio priorities, business objectives and development strategies

An enterprise capability partner

As a long-time leader in FSP outsourcing, Parexel brings decades of experience and perspective to this next evolution of the model. FSP Integrated Solutions helps customers extend both capacity and capability through a flexible, integrated approach that spans clinical development and post-approval lifecycle management.

Supported by more than 8,000 FSP professionals globally, we are bringing together expertise, technology, governance and delivery within a single coordinated framework designed to improve productivity and simplify execution. What excites me most about this evolution is the opportunity to make those capabilities easier for customers to access through a more integrated and accountable model.

Across the industry, I see organizations under pressure to improve productivity while managing increasingly complex development and post-approval demands. At the same time, they are looking for greater flexibility, access to specialized expertise and partners that can adapt alongside their business. FSP Integrated Solutions is built to help meet those needs while keeping the focus where it belongs: delivering meaningful outcomes for customers and patients.

Through this new approach, we will:

• Build flexible global operating models designed with sponsors’ long-term business objectives in mind
• Scale capacity and capability as pipeline demands change, with access to global infrastructure, local expertise, and specialist talent
• Use ParexelAI™ to support human decision-makers, automate manual work and improve productivity
• Access integrated capabilities across clinical development, regulatory, safety and post-approval activities through a single coordinated model

We are already helping customers apply this approach across a range of transformation initiatives. From global pharmaceutical companies redesigning clinical development operating models to organizations looking for more flexible ways to access expertise, the common goal is the same: improving productivity while maintaining control, quality and oversight:

• For a top pharma customer, we are supporting the transformation of their global clinical development operating model by transitioning more than 70 studies in over 40 countries from FSO to FSP using a four-phase plan. This will allow the sponsor to access specialized.
• In another partnership with a large pharma company, we’re supporting global site maintenance and monitoring for a single therapeutic area portfolio through an integrated delivery approach designed to balance flexibility, quality and operational performance. We’ve created a shared team culture and have set benchmarks for timelines. 

What these examples have in common is that neither customer was looking for more resources alone. They were looking for a more effective way to access expertise, improve productivity and support long-term organizational goals. That shift is increasingly what I see across the industry.

Parexel brings deep therapeutic, scientific, operational and regulatory expertise to FSP Integrated Solutions, along with substantial investments in AI and technology. Our teams work seamlessly across delivery hubs in North and South America, Europe, and Asia Pacific, all motivated by a shared purpose: reducing complexity to ensure patient safety and accelerate access to critical therapies.

Could the new FSP model benefit your organization? Let’s talk about how our fit-for-purpose approach creates the foundation for seamless partnerships.
 

Start a conversation

Return to Insights Center